21st Austria weekly - Valneva Rosenbauer 23/06/2022 [pic1]Valneva: Valneva SE an Austrian/French specialty vaccine company today announced that the Committee for Medicinal Products Human Use CHMP of European Medicines Agency EMA has recommended marketing authorization in Europe Valneva’s
21st Austria weekly - Valneva Erste Group 16/06/2022 [pic1]Valneva: an Austrian/French specialty vaccine company today announced that it has entered into a settlement agreement with the Government of United Kingdom “HMG” in relation to termination supply for Valneva’s COVID-19 candidate VLA2001. The Company on September 13 2021 had received notice from HMG and termination which Valneva accepted basis HMG’s
21st Austria weekly - Valneva Andritz 16/05/2022 [pic1]Valneva: an Austrian/French specialty vaccine company announced that it has received a notice from the European Commission EC of intent to terminate advance purchase agreement APA for Valneva’s inactivated whole-virus COVID-19 candidate VLA2001. The APA provides EC with right if VLA2001 had not marketing authorization Medicines Agency
21st Austria weekly - Valneva EVN 25/02/2022 [pic1]Valneva: Valneva SE an Austrian/French specialty vaccine company today announced that the Committee for Medicinal Products Human Use CHMP of European Medicines Agency EMA has provided initial assessment Valneva’s inactivated adjuvanted COVID-19
21st Austria weekly - Valneva EVN 25/02/2022 [pic1]Valneva: Valneva SE an Austrian/French specialty vaccine company today announced that the Committee for Medicinal Products Human Use CHMP of European Medicines Agency EMA has provided initial assessment Valneva’s inactivated adjuvanted COVID-19